Activity and Safety of Synthetic Lectins Based on Benzoboroxole-Functionalized Polymers for Inhibition of HIV Entry
Identifieur interne : 000C68 ( Main/Exploration ); précédent : 000C67; suivant : 000C69Activity and Safety of Synthetic Lectins Based on Benzoboroxole-Functionalized Polymers for Inhibition of HIV Entry
Auteurs : Alamelu Mahalingam [États-Unis] ; Anthony R. Geonnotti [États-Unis] ; Jan Balzarini [Belgique] ; Patrick F. Kiser [États-Unis]Source :
- Molecular pharmaceutics [ 1543-8384 ] ; 2011.
Abstract
Lectins derived from plant and microbial sources constitute a vital class of entry inhibitors that target the oligomannose residues on the HIV envelope gp120. Despite their potency and specificity, success of lectin-based entry inhibitors may be impeded by issues in regards to economical production, formulation and potential mitogenicity. Therefore, there exists a gap in the HIV therapeutics pipeline that underscores the need for mass producible, synthetic, broad-spectrum, and biocomptabile inhibitors of HIV entry. Here, we present the development of a polymeric synthetic lectin, based on benzoboroxole (BzB), which exhibits weak affinity (~25 M−1) for non-reducing sugars, similar to those found on the HIV envelope. High molecular weight BzB-functionalized polymers demonstrated antiviral activity that increased with an increase in ligand density and molecular weight of the polymer construct; revealing that polyvalency improves activity. Polymers showed significant increase in activity from 25 to 75 mol% BzB functionalization with EC50 of 15 μM and 15 nM, respectively. A further increase in mole functionalization to 90% resulted in an increase of the EC50 (59 ± 5 nM), likely due to the elongated rigid structure of the polymer chain compelled by electrostatic repulsion between the boronic acid groups. An increase in molecular weight of the polymer at 50 mol% BzB functionalization showed a gradual but significant increase in antiviral activity, with the highest activity seen with the 382 kDa polymer (EC50 of 1.1 ± 0.5 nM in CEM cells and 11 ± 3 nM in TZM-bl cells). Supplementing the polymer backbone with 10 mol% sulfonic acid not only increased the aqueous solubility of the polymers by at least 50-fold, but also demonstrated a synergistic increase in anti-HIV activity (4.0 ± 1.5 nM in TZM-bl cells), possibly due to electrostatic interactions between the negatively charged polymer backbone and the positively charged V3-loop in the gp120. The benzoboroxole-sulfonic acid copolymers showed no decrease in activity in the presence of a seminal concentration of fructose (p > 0.05). Additionally, the co-polymers exhibit minimal, if any effect on the cellular viability, barrier properties, or cytokine levels in human reconstructed ecto-cervical tissue after 3 days of repeated exposure and did not show pronounced activity against a variety of other RNA and DNA viruses.
Url:
DOI: 10.1021/mp2002957
PubMed: 21879735
PubMed Central: 3445258
Affiliations:
- Belgique, États-Unis
- Caroline du Nord, Province du Brabant flamand, Région flamande, Utah
- Louvain
- Katholieke Universiteit Leuven
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000505
- to stream Pmc, to step Curation: 000505
- to stream Pmc, to step Checkpoint: 000576
- to stream Ncbi, to step Merge: 000235
- to stream Ncbi, to step Curation: 000235
- to stream Ncbi, to step Checkpoint: 000235
- to stream Main, to step Merge: 000C70
- to stream Main, to step Curation: 000C68
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Activity and Safety of Synthetic Lectins Based on Benzoboroxole-Functionalized Polymers for Inhibition of HIV Entry</title>
<author><name sortKey="Mahalingam, Alamelu" sort="Mahalingam, Alamelu" uniqKey="Mahalingam A" first="Alamelu" last="Mahalingam">Alamelu Mahalingam</name>
<affiliation wicri:level="2"><nlm:aff id="A1">Departments of Pharmaceutics and Pharmaceutical Chemistry and Bioengineering, University of Utah, Salt Lake City, Utah 84112-5820</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Utah</region>
</placeName>
<wicri:cityArea>Departments of Pharmaceutics and Pharmaceutical Chemistry and Bioengineering, University of Utah, Salt Lake City</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Geonnotti, Anthony R" sort="Geonnotti, Anthony R" uniqKey="Geonnotti A" first="Anthony R." last="Geonnotti">Anthony R. Geonnotti</name>
<affiliation wicri:level="2"><nlm:aff id="A2">Duke University Medical Center, Durham, North Carolina 27708-0281</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
<wicri:cityArea>Duke University Medical Center, Durham</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Balzarini, Jan" sort="Balzarini, Jan" uniqKey="Balzarini J" first="Jan" last="Balzarini">Jan Balzarini</name>
<affiliation wicri:level="4"><nlm:aff id="A3">Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium</nlm:aff>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, B-3000 Leuven</wicri:regionArea>
<orgName type="university">Katholieke Universiteit Leuven</orgName>
<placeName><settlement type="city">Louvain</settlement>
<region>Région flamande</region>
<region type="district" nuts="2">Province du Brabant flamand</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kiser, Patrick F" sort="Kiser, Patrick F" uniqKey="Kiser P" first="Patrick F." last="Kiser">Patrick F. Kiser</name>
<affiliation wicri:level="2"><nlm:aff id="A1">Departments of Pharmaceutics and Pharmaceutical Chemistry and Bioengineering, University of Utah, Salt Lake City, Utah 84112-5820</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Utah</region>
</placeName>
<wicri:cityArea>Departments of Pharmaceutics and Pharmaceutical Chemistry and Bioengineering, University of Utah, Salt Lake City</wicri:cityArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">21879735</idno>
<idno type="pmc">3445258</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3445258</idno>
<idno type="RBID">PMC:3445258</idno>
<idno type="doi">10.1021/mp2002957</idno>
<date when="2011">2011</date>
<idno type="wicri:Area/Pmc/Corpus">000505</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000505</idno>
<idno type="wicri:Area/Pmc/Curation">000505</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000505</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000576</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000576</idno>
<idno type="wicri:Area/Ncbi/Merge">000235</idno>
<idno type="wicri:Area/Ncbi/Curation">000235</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000235</idno>
<idno type="wicri:doubleKey">1543-8384:2011:Mahalingam A:activity:and:safety</idno>
<idno type="wicri:Area/Main/Merge">000C70</idno>
<idno type="wicri:Area/Main/Curation">000C68</idno>
<idno type="wicri:Area/Main/Exploration">000C68</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Activity and Safety of Synthetic Lectins Based on Benzoboroxole-Functionalized Polymers for Inhibition of HIV Entry</title>
<author><name sortKey="Mahalingam, Alamelu" sort="Mahalingam, Alamelu" uniqKey="Mahalingam A" first="Alamelu" last="Mahalingam">Alamelu Mahalingam</name>
<affiliation wicri:level="2"><nlm:aff id="A1">Departments of Pharmaceutics and Pharmaceutical Chemistry and Bioengineering, University of Utah, Salt Lake City, Utah 84112-5820</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Utah</region>
</placeName>
<wicri:cityArea>Departments of Pharmaceutics and Pharmaceutical Chemistry and Bioengineering, University of Utah, Salt Lake City</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Geonnotti, Anthony R" sort="Geonnotti, Anthony R" uniqKey="Geonnotti A" first="Anthony R." last="Geonnotti">Anthony R. Geonnotti</name>
<affiliation wicri:level="2"><nlm:aff id="A2">Duke University Medical Center, Durham, North Carolina 27708-0281</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
<wicri:cityArea>Duke University Medical Center, Durham</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Balzarini, Jan" sort="Balzarini, Jan" uniqKey="Balzarini J" first="Jan" last="Balzarini">Jan Balzarini</name>
<affiliation wicri:level="4"><nlm:aff id="A3">Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium</nlm:aff>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, B-3000 Leuven</wicri:regionArea>
<orgName type="university">Katholieke Universiteit Leuven</orgName>
<placeName><settlement type="city">Louvain</settlement>
<region>Région flamande</region>
<region type="district" nuts="2">Province du Brabant flamand</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kiser, Patrick F" sort="Kiser, Patrick F" uniqKey="Kiser P" first="Patrick F." last="Kiser">Patrick F. Kiser</name>
<affiliation wicri:level="2"><nlm:aff id="A1">Departments of Pharmaceutics and Pharmaceutical Chemistry and Bioengineering, University of Utah, Salt Lake City, Utah 84112-5820</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Utah</region>
</placeName>
<wicri:cityArea>Departments of Pharmaceutics and Pharmaceutical Chemistry and Bioengineering, University of Utah, Salt Lake City</wicri:cityArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Molecular pharmaceutics</title>
<idno type="ISSN">1543-8384</idno>
<idno type="eISSN">1543-8392</idno>
<imprint><date when="2011">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p id="P1">Lectins derived from plant and microbial sources constitute a vital class of entry inhibitors that target the oligomannose residues on the HIV envelope gp120. Despite their potency and specificity, success of lectin-based entry inhibitors may be impeded by issues in regards to economical production, formulation and potential mitogenicity. Therefore, there exists a gap in the HIV therapeutics pipeline that underscores the need for mass producible, synthetic, broad-spectrum, and biocomptabile inhibitors of HIV entry. Here, we present the development of a polymeric synthetic lectin, based on benzoboroxole (BzB), which exhibits weak affinity (~25 M<sup>−1</sup>
) for non-reducing sugars, similar to those found on the HIV envelope. High molecular weight BzB-functionalized polymers demonstrated antiviral activity that increased with an increase in ligand density and molecular weight of the polymer construct; revealing that polyvalency improves activity. Polymers showed significant increase in activity from 25 to 75 mol% BzB functionalization with EC<sub>50</sub>
of 15 μM and 15 nM, respectively. A further increase in mole functionalization to 90% resulted in an increase of the EC<sub>50</sub>
(59 ± 5 nM), likely due to the elongated rigid structure of the polymer chain compelled by electrostatic repulsion between the boronic acid groups. An increase in molecular weight of the polymer at 50 mol% BzB functionalization showed a gradual but significant increase in antiviral activity, with the highest activity seen with the 382 kDa polymer (EC<sub>50</sub>
of 1.1 ± 0.5 nM in CEM cells and 11 ± 3 nM in TZM-bl cells). Supplementing the polymer backbone with 10 mol% sulfonic acid not only increased the aqueous solubility of the polymers by at least 50-fold, but also demonstrated a synergistic increase in anti-HIV activity (4.0 ± 1.5 nM in TZM-bl cells), possibly due to electrostatic interactions between the negatively charged polymer backbone and the positively charged V3-loop in the gp120. The benzoboroxole-sulfonic acid copolymers showed no decrease in activity in the presence of a seminal concentration of fructose (p > 0.05). Additionally, the co-polymers exhibit minimal, if any effect on the cellular viability, barrier properties, or cytokine levels in human reconstructed ecto-cervical tissue after 3 days of repeated exposure and did not show pronounced activity against a variety of other RNA and DNA viruses.</p>
</div>
</front>
</TEI>
<affiliations><list><country><li>Belgique</li>
<li>États-Unis</li>
</country>
<region><li>Caroline du Nord</li>
<li>Province du Brabant flamand</li>
<li>Région flamande</li>
<li>Utah</li>
</region>
<settlement><li>Louvain</li>
</settlement>
<orgName><li>Katholieke Universiteit Leuven</li>
</orgName>
</list>
<tree><country name="États-Unis"><region name="Utah"><name sortKey="Mahalingam, Alamelu" sort="Mahalingam, Alamelu" uniqKey="Mahalingam A" first="Alamelu" last="Mahalingam">Alamelu Mahalingam</name>
</region>
<name sortKey="Geonnotti, Anthony R" sort="Geonnotti, Anthony R" uniqKey="Geonnotti A" first="Anthony R." last="Geonnotti">Anthony R. Geonnotti</name>
<name sortKey="Kiser, Patrick F" sort="Kiser, Patrick F" uniqKey="Kiser P" first="Patrick F." last="Kiser">Patrick F. Kiser</name>
</country>
<country name="Belgique"><region name="Région flamande"><name sortKey="Balzarini, Jan" sort="Balzarini, Jan" uniqKey="Balzarini J" first="Jan" last="Balzarini">Jan Balzarini</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C68 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000C68 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= CovidV1 |flux= Main |étape= Exploration |type= RBID |clé= PMC:3445258 |texte= Activity and Safety of Synthetic Lectins Based on Benzoboroxole-Functionalized Polymers for Inhibition of HIV Entry }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:21879735" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a CovidV1
This area was generated with Dilib version V0.6.33. |